NASDAQ:CRBP

Corbus Pharmaceuticals Stock Forecast, Price & News

$1.37
-0.03 (-2.14 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.31
$1.44
50-Day Range
$1.37
$2.21
52-Week Range
$0.91
$9.78
Volume1.24 million shs
Average Volume1.12 million shs
Market Capitalization$171.29 million
P/E RatioN/A
Dividend YieldN/A
Beta1.77
30 days | 90 days | 365 days | Advanced Chart
Receive CRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Corbus Pharmaceuticals logo

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.73 out of 5 stars

Medical Sector

394th out of 842 stocks

Pharmaceutical Preparations Industry

176th out of 324 stocks

Analyst Opinion: 3.1Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions

Is Corbus Pharmaceuticals a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Corbus Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRBP, but not buy additional shares or sell existing shares.
View analyst ratings for Corbus Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Corbus Pharmaceuticals?

Wall Street analysts have given Corbus Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Corbus Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Corbus Pharmaceuticals?

Corbus Pharmaceuticals saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 8,360,000 shares, a drop of 42.3% from the June 15th total of 14,480,000 shares. Based on an average daily volume of 3,050,000 shares, the days-to-cover ratio is presently 2.7 days. Currently, 6.8% of the company's stock are sold short.
View Corbus Pharmaceuticals' Short Interest
.

When is Corbus Pharmaceuticals' next earnings date?

Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Corbus Pharmaceuticals
.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) issued its earnings results on Thursday, May, 13th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.01. The biopharmaceutical company earned $0.65 million during the quarter, compared to analyst estimates of $0.95 million. Corbus Pharmaceuticals had a negative trailing twelve-month return on equity of 182.21% and a negative net margin of 3,460.04%.
View Corbus Pharmaceuticals' earnings history
.

How has Corbus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Corbus Pharmaceuticals' stock was trading at $4.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRBP stock has decreased by 66.7% and is now trading at $1.37.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CRBP?

6 analysts have issued twelve-month price objectives for Corbus Pharmaceuticals' stock. Their forecasts range from $2.50 to $3.00. On average, they anticipate Corbus Pharmaceuticals' stock price to reach $2.88 in the next year. This suggests a possible upside of 109.9% from the stock's current price.
View analysts' price targets for Corbus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Corbus Pharmaceuticals' key executives?

Corbus Pharmaceuticals' management team includes the following people:
  • Dr. Yuval Cohen, CEO & Director (Age 46, Pay $827.32k)
  • Mr. Sean F. Moran CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 63, Pay $528k)
  • Dr. Barbara White, Head of Research & Chief Medical Officer (Age 71, Pay $579.48k)
  • Ted Jenkins, Sr. Director of Investor Relations & Corp. Communications
  • Scott Constantine, Sr. Director & Head of Clinical Operations
  • Mr. Craig Stuart Millian M.B.A., Chief Commercial Officer (Age 53)
  • Mr. Dylan Wenke, Head of Bus. Devel.

Who are some of Corbus Pharmaceuticals' key competitors?

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), (CGC), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Davy Global Fund Management Ltd (2.31%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, Craig Stuart Millian, Robert Paul Discordia, Sean F Moran and Yuval Cohen.
View institutional ownership trends for Corbus Pharmaceuticals
.

Which major investors are buying Corbus Pharmaceuticals stock?

CRBP stock was acquired by a variety of institutional investors in the last quarter, including Davy Global Fund Management Ltd. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Barbara White, Craig Stuart Millian, Robert Paul Discordia, and Yuval Cohen.
View insider buying and selling activity for Corbus Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $1.37.

How much money does Corbus Pharmaceuticals make?

Corbus Pharmaceuticals has a market capitalization of $171.29 million and generates $3.94 million in revenue each year. The biopharmaceutical company earns $-111,270,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis.

How many employees does Corbus Pharmaceuticals have?

Corbus Pharmaceuticals employs 76 workers across the globe.

What is Corbus Pharmaceuticals' official website?

The official website for Corbus Pharmaceuticals is www.corbuspharma.com.

Where are Corbus Pharmaceuticals' headquarters?

Corbus Pharmaceuticals is headquartered at 500 River Ridge Drive, Norwood MA, 02062.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]


This page was last updated on 8/1/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.